Ariosa Diagnostics, Inc. is a global molecular diagnostics company committed to improving overall patient care by developing and delivering innovative, affordable, and widely-accessible testing services through its CLIA laboratory. Tests are fully validated to CLIA requirements by rigorous and comprehensive methodologies to ensure healthcare practitioners and patients can be confident in the test’s performance. Ariosa has developed the technologies to perform a directed analysis of cell-free DNA in blood.
NEW YORK, June 27 (Reuters) - The U.S. Supreme Court on
Monday rejected a bid to review a legal fight over the
cancellation of a patent on a less-risky form of prenatal
testing, in a case that has left many companies and trade groups
worried that important discoveries may no longer qualify for
NEW YORK (Reuters) - Companies, trade groups and universities who fear that many important discoveries may no longer qualify for patents are among a broad coalition urging the U.S. Supreme Court to review the cancellation of a patent on a less risky form of prenatal testing.